KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for West Pharmaceutical Services (WST) over the last 8 years, with Q3 2025 value amounting to $300000.0.

  • West Pharmaceutical Services' Asset Writedowns and Impairment fell 7000.0% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 11304.35%. This contributed to the annual value of $7.3 million for FY2024, which is 2395.83% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported Asset Writedowns and Impairment of $300000.0 as of Q3 2025, which was down 7000.0% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Asset Writedowns and Impairment registered a high of $5.4 million during Q4 2024, and its lowest value of $200000.0 during Q2 2022.
  • In the last 4 years, West Pharmaceutical Services' Asset Writedowns and Impairment had a median value of $1.4 million in 2022 and averaged $2.0 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Asset Writedowns and Impairment plummeted by 8000.0% in 2024, and later skyrocketed by 116666.67% in 2025.
  • West Pharmaceutical Services' Asset Writedowns and Impairment (Quarter) stood at $4.6 million in 2022, then crashed by 41.3% to $2.7 million in 2023, then soared by 100.0% to $5.4 million in 2024, then plummeted by 94.44% to $300000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $300000.0 for Q3 2025, versus $3.8 million for Q2 2025 and $300000.0 for Q1 2025.